David Fox
Concepts (625)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 57 | 2026 | 1180 | 5.740 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 18 | 2026 | 104 | 5.310 |
Why?
| | Antigens, CD | 20 | 2026 | 558 | 4.670 |
Why?
| | CD13 Antigens | 7 | 2026 | 11 | 2.720 |
Why?
| | Synovial Membrane | 20 | 2026 | 123 | 2.710 |
Why?
| | Scleroderma, Systemic | 10 | 2026 | 123 | 2.210 |
Why?
| | Immunotherapy | 5 | 2026 | 666 | 2.050 |
Why?
| | Fibroblasts | 20 | 2026 | 1025 | 1.900 |
Why?
| | Th17 Cells | 8 | 2020 | 101 | 1.820 |
Why?
| | Interleukin-17 | 10 | 2015 | 120 | 1.790 |
Why?
| | T-Lymphocytes | 21 | 2024 | 1996 | 1.580 |
Why?
| | Gastrostomy | 4 | 2016 | 130 | 1.510 |
Why?
| | Inflammation | 16 | 2026 | 2878 | 1.380 |
Why?
| | Scleroderma, Diffuse | 6 | 2022 | 10 | 1.380 |
Why?
| | Arthritis, Experimental | 10 | 2026 | 136 | 1.360 |
Why?
| | Arthritis | 3 | 2026 | 96 | 1.300 |
Why?
| | Interleukin-4 | 4 | 2013 | 207 | 1.230 |
Why?
| | Neoplasms | 7 | 2026 | 2906 | 1.210 |
Why?
| | Rheumatology | 8 | 2019 | 133 | 1.190 |
Why?
| | T-Lymphocyte Subsets | 8 | 2020 | 418 | 1.100 |
Why?
| | Lymphocyte Activation | 11 | 2026 | 1132 | 1.080 |
Why?
| | Autoimmune Diseases | 9 | 2025 | 468 | 1.000 |
Why?
| | Cytokines | 15 | 2026 | 2067 | 0.950 |
Why?
| | Cell Communication | 8 | 2017 | 328 | 0.930 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2026 | 224 | 0.920 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2026 | 76 | 0.890 |
Why?
| | Fundoplication | 2 | 2016 | 52 | 0.850 |
Why?
| | Antirheumatic Agents | 9 | 2026 | 307 | 0.850 |
Why?
| | Autoantigens | 6 | 2020 | 427 | 0.820 |
Why?
| | Neutrophils | 7 | 2025 | 1124 | 0.810 |
Why?
| | Autoimmunity | 3 | 2026 | 933 | 0.810 |
Why?
| | Humans | 130 | 2026 | 145475 | 0.800 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2026 | 218 | 0.780 |
Why?
| | Rheumatic Diseases | 7 | 2024 | 98 | 0.760 |
Why?
| | Tumor Necrosis Factor-alpha | 9 | 2026 | 1217 | 0.740 |
Why?
| | Animals | 59 | 2026 | 38030 | 0.740 |
Why?
| | Antifungal Agents | 4 | 2022 | 151 | 0.730 |
Why?
| | Neoplastic Stem Cells | 1 | 2026 | 409 | 0.720 |
Why?
| | Gastroesophageal Reflux | 2 | 2016 | 237 | 0.720 |
Why?
| | Extracellular Traps | 4 | 2026 | 52 | 0.720 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2026 | 1140 | 0.720 |
Why?
| | Killer Cells, Natural | 2 | 2026 | 480 | 0.710 |
Why?
| | Enteral Nutrition | 2 | 2014 | 217 | 0.710 |
Why?
| | Immune System Diseases | 2 | 2014 | 37 | 0.690 |
Why?
| | Psoriasis | 2 | 2023 | 115 | 0.680 |
Why?
| | Silicones | 5 | 2017 | 31 | 0.630 |
Why?
| | B-Lymphocytes | 6 | 2025 | 870 | 0.600 |
Why?
| | Cells, Cultured | 21 | 2026 | 4148 | 0.590 |
Why?
| | Neovascularization, Physiologic | 4 | 2019 | 192 | 0.580 |
Why?
| | Antibodies, Monoclonal | 11 | 2026 | 1505 | 0.580 |
Why?
| | Autoantibodies | 7 | 2026 | 1509 | 0.540 |
Why?
| | Metacarpophalangeal Joint | 6 | 2014 | 22 | 0.530 |
Why?
| | Mice | 35 | 2026 | 18329 | 0.530 |
Why?
| | Multiple Sclerosis | 4 | 2026 | 489 | 0.500 |
Why?
| | Anti-Inflammatory Agents | 2 | 2020 | 477 | 0.500 |
Why?
| | Synoviocytes | 6 | 2026 | 18 | 0.500 |
Why?
| | Skin | 8 | 2024 | 753 | 0.490 |
Why?
| | Interferon-gamma | 5 | 2019 | 784 | 0.480 |
Why?
| | Antigen-Presenting Cells | 7 | 2010 | 159 | 0.480 |
Why?
| | Fibrosis | 5 | 2024 | 559 | 0.480 |
Why?
| | Hand Deformities, Acquired | 3 | 2013 | 4 | 0.480 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 65 | 0.470 |
Why?
| | Decision Making | 2 | 2014 | 977 | 0.470 |
Why?
| | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2015 | 3 | 0.460 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 919 | 0.460 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 271 | 0.460 |
Why?
| | Dinoprost | 1 | 2015 | 49 | 0.450 |
Why?
| | Joint Prosthesis | 3 | 2017 | 22 | 0.450 |
Why?
| | Hyaluronan Receptors | 2 | 2026 | 104 | 0.450 |
Why?
| | Delivery of Health Care | 2 | 2012 | 946 | 0.430 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2018 | 552 | 0.420 |
Why?
| | Immunoconjugates | 3 | 2023 | 138 | 0.420 |
Why?
| | Signal Transduction | 13 | 2026 | 5216 | 0.420 |
Why?
| | Cell Adhesion Molecules | 4 | 2024 | 181 | 0.420 |
Why?
| | Chemotaxis | 1 | 2015 | 122 | 0.420 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2014 | 6 | 0.410 |
Why?
| | Gastroscopy | 1 | 2014 | 18 | 0.410 |
Why?
| | Periostitis | 1 | 2013 | 4 | 0.410 |
Why?
| | Intubation, Gastrointestinal | 1 | 2014 | 81 | 0.410 |
Why?
| | Societies, Medical | 2 | 2009 | 899 | 0.400 |
Why?
| | Professional-Family Relations | 2 | 2014 | 153 | 0.400 |
Why?
| | MAP Kinase Kinase Kinases | 3 | 2019 | 70 | 0.400 |
Why?
| | Fas Ligand Protein | 2 | 2013 | 61 | 0.400 |
Why?
| | Arthralgia | 1 | 2013 | 61 | 0.380 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 992 | 0.380 |
Why?
| | Cell Differentiation | 7 | 2019 | 2046 | 0.380 |
Why?
| | Coculture Techniques | 6 | 2013 | 247 | 0.380 |
Why?
| | Female | 48 | 2026 | 78845 | 0.380 |
Why?
| | Hospital Medicine | 1 | 2014 | 97 | 0.370 |
Why?
| | Benzyl Compounds | 2 | 2024 | 2 | 0.370 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2214 | 0.360 |
Why?
| | Bone Resorption | 3 | 2020 | 81 | 0.360 |
Why?
| | Endothelial Cells | 7 | 2022 | 874 | 0.360 |
Why?
| | Patient Navigation | 1 | 2014 | 126 | 0.360 |
Why?
| | Dendritic Cells | 2 | 2007 | 499 | 0.360 |
Why?
| | Triazoles | 1 | 2013 | 187 | 0.360 |
Why?
| | Epitopes | 4 | 2013 | 473 | 0.360 |
Why?
| | Azetidines | 2 | 2024 | 45 | 0.360 |
Why?
| | Male | 45 | 2026 | 72843 | 0.350 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 2 | 2024 | 28 | 0.350 |
Why?
| | Growth Inhibitors | 1 | 2011 | 39 | 0.350 |
Why?
| | Anti-Citrullinated Protein Antibodies | 2 | 2026 | 127 | 0.350 |
Why?
| | Pyrimidines | 2 | 2022 | 530 | 0.340 |
Why?
| | Receptors, Interleukin-4 | 1 | 2011 | 16 | 0.340 |
Why?
| | Leukocytes, Mononuclear | 2 | 2026 | 574 | 0.330 |
Why?
| | Cryptococcus neoformans | 2 | 2022 | 21 | 0.330 |
Why?
| | Molecular Targeted Therapy | 5 | 2018 | 439 | 0.320 |
Why?
| | CD40 Ligand | 2 | 2007 | 40 | 0.320 |
Why?
| | General Surgery | 2 | 2012 | 206 | 0.310 |
Why?
| | Teaching Rounds | 1 | 2011 | 74 | 0.310 |
Why?
| | Histones | 3 | 2026 | 666 | 0.310 |
Why?
| | CD5 Antigens | 1 | 2009 | 10 | 0.300 |
Why?
| | Tacrolimus | 2 | 2022 | 196 | 0.300 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3542 | 0.300 |
Why?
| | Ulna | 1 | 2009 | 35 | 0.290 |
Why?
| | Lymphocytes | 2 | 2024 | 376 | 0.290 |
Why?
| | Transcriptome | 2 | 2026 | 1038 | 0.290 |
Why?
| | B7-1 Antigen | 2 | 2010 | 55 | 0.290 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2019 | 15 | 0.290 |
Why?
| | Phosphodiesterase 4 Inhibitors | 2 | 2019 | 12 | 0.290 |
Why?
| | Uveitis | 2 | 2022 | 149 | 0.290 |
Why?
| | B-Lymphocyte Subsets | 1 | 2009 | 76 | 0.290 |
Why?
| | Ligands | 4 | 2025 | 665 | 0.280 |
Why?
| | Apoptosis | 5 | 2026 | 2440 | 0.280 |
Why?
| | Middle Aged | 26 | 2026 | 36215 | 0.270 |
Why?
| | Neovascularization, Pathologic | 3 | 2020 | 286 | 0.270 |
Why?
| | Inhibitor of Differentiation Protein 1 | 2 | 2019 | 8 | 0.270 |
Why?
| | Disease Management | 1 | 2012 | 653 | 0.270 |
Why?
| | Pediatrics | 2 | 2014 | 1121 | 0.260 |
Why?
| | Peer Review, Research | 1 | 2008 | 36 | 0.260 |
Why?
| | Benzamides | 2 | 2019 | 226 | 0.260 |
Why?
| | Hospitals, Pediatric | 1 | 2011 | 558 | 0.260 |
Why?
| | Mice, Inbred DBA | 5 | 2020 | 182 | 0.260 |
Why?
| | Benzimidazoles | 2 | 2019 | 189 | 0.260 |
Why?
| | Arthroplasty | 5 | 2017 | 59 | 0.260 |
Why?
| | Collagen Type II | 3 | 2020 | 53 | 0.250 |
Why?
| | Graft vs Host Disease | 2 | 2023 | 279 | 0.250 |
Why?
| | Macrophages | 4 | 2019 | 1507 | 0.250 |
Why?
| | Serum Response Factor | 2 | 2019 | 33 | 0.250 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2017 | 69 | 0.250 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 208 | 0.250 |
Why?
| | Program Development | 1 | 2009 | 368 | 0.240 |
Why?
| | Family | 1 | 2011 | 682 | 0.240 |
Why?
| | Adult | 22 | 2026 | 40777 | 0.240 |
Why?
| | Postoperative Complications | 3 | 2014 | 2970 | 0.240 |
Why?
| | TWEAK Receptor | 1 | 2026 | 6 | 0.240 |
Why?
| | Drug Design | 2 | 2019 | 175 | 0.240 |
Why?
| | Nipecotic Acids | 2 | 2017 | 6 | 0.230 |
Why?
| | Glycoproteins | 2 | 2001 | 354 | 0.230 |
Why?
| | Sjogren's Syndrome | 1 | 2025 | 37 | 0.230 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2026 | 83 | 0.230 |
Why?
| | Hydroxychloroquine | 1 | 2026 | 65 | 0.220 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 62 | 0.220 |
Why?
| | Citrulline | 3 | 2020 | 45 | 0.220 |
Why?
| | Stromal Cells | 1 | 2025 | 121 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2158 | 0.220 |
Why?
| | Mice, Inbred C57BL | 13 | 2019 | 5983 | 0.220 |
Why?
| | Periodicals as Topic | 1 | 2008 | 209 | 0.220 |
Why?
| | Abatacept | 3 | 2022 | 56 | 0.220 |
Why?
| | Th2 Cells | 3 | 2013 | 175 | 0.220 |
Why?
| | Aged | 17 | 2026 | 26153 | 0.220 |
Why?
| | Glucocorticoids | 2 | 2019 | 531 | 0.220 |
Why?
| | Osteoblasts | 1 | 2005 | 145 | 0.220 |
Why?
| | Antigen Presentation | 2 | 2020 | 207 | 0.210 |
Why?
| | Rituximab | 1 | 2025 | 210 | 0.210 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2024 | 29 | 0.210 |
Why?
| | Actomyosin | 1 | 2024 | 20 | 0.210 |
Why?
| | Interleukin-7 | 2 | 2026 | 66 | 0.200 |
Why?
| | Benzylisoquinolines | 1 | 2023 | 2 | 0.200 |
Why?
| | Antiphospholipid Syndrome | 1 | 2024 | 37 | 0.200 |
Why?
| | Cell Membrane | 1 | 2007 | 707 | 0.200 |
Why?
| | Arthroplasty, Replacement | 2 | 2015 | 47 | 0.200 |
Why?
| | Tacrolimus Binding Protein 1A | 2 | 2022 | 10 | 0.200 |
Why?
| | Lymphoma, T-Cell | 1 | 2023 | 29 | 0.200 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 55 | 0.190 |
Why?
| | Calcineurin Inhibitors | 2 | 2022 | 69 | 0.190 |
Why?
| | Arthroplasty, Replacement, Finger | 2 | 2014 | 3 | 0.190 |
Why?
| | Primary Health Care | 2 | 2019 | 1735 | 0.190 |
Why?
| | Mice, Transgenic | 6 | 2020 | 2188 | 0.190 |
Why?
| | Transcription, Genetic | 4 | 2019 | 1454 | 0.190 |
Why?
| | Optic Neuritis | 1 | 2023 | 44 | 0.190 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 848 | 0.190 |
Why?
| | Retinal Pigments | 1 | 2022 | 6 | 0.190 |
Why?
| | Sulfatases | 1 | 2022 | 5 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2025 | 238 | 0.190 |
Why?
| | Calcineurin | 2 | 2022 | 105 | 0.190 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2022 | 49 | 0.190 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 147 | 0.180 |
Why?
| | Mice, SCID | 2 | 2021 | 369 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2378 | 0.180 |
Why?
| | Lipid Metabolism | 1 | 2025 | 529 | 0.180 |
Why?
| | Phagocytosis | 2 | 2023 | 296 | 0.180 |
Why?
| | Osteoarthritis | 3 | 2019 | 200 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2015 | 425 | 0.170 |
Why?
| | Transforming Growth Factor beta | 3 | 2024 | 474 | 0.170 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2001 | 16 | 0.170 |
Why?
| | Trans-Activators | 3 | 2019 | 396 | 0.170 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2001 | 20 | 0.170 |
Why?
| | Gangliosides | 1 | 2001 | 23 | 0.170 |
Why?
| | Quantitative Trait Loci | 1 | 2023 | 378 | 0.170 |
Why?
| | Pyrroles | 1 | 2022 | 220 | 0.170 |
Why?
| | Cell Movement | 4 | 2019 | 959 | 0.170 |
Why?
| | Monocytes | 3 | 2019 | 539 | 0.160 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 77 | 0.160 |
Why?
| | Hemeproteins | 1 | 2020 | 8 | 0.160 |
Why?
| | Malassezia | 1 | 2020 | 5 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2021 | 93 | 0.160 |
Why?
| | Prospective Studies | 8 | 2021 | 8057 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2026 | 699 | 0.160 |
Why?
| | Colitis | 1 | 2023 | 280 | 0.160 |
Why?
| | Receptors, Lysosphingolipid | 1 | 2020 | 13 | 0.160 |
Why?
| | Receptors, Cytokine | 1 | 2020 | 36 | 0.150 |
Why?
| | Crystallography, X-Ray | 5 | 2020 | 486 | 0.150 |
Why?
| | Patient Readmission | 2 | 2016 | 769 | 0.150 |
Why?
| | Aspergillus fumigatus | 1 | 2019 | 26 | 0.150 |
Why?
| | Interleukin-10 | 2 | 2013 | 309 | 0.150 |
Why?
| | Disease Models, Animal | 9 | 2022 | 4560 | 0.150 |
Why?
| | Interferons | 1 | 2021 | 186 | 0.150 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 21 | 0.150 |
Why?
| | Citrullination | 1 | 2019 | 12 | 0.150 |
Why?
| | Complement C5 | 1 | 2019 | 33 | 0.150 |
Why?
| | Retina | 2 | 2022 | 326 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 734 | 0.150 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2019 | 25 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 37 | 0.150 |
Why?
| | Carboxylic Acids | 1 | 2019 | 31 | 0.150 |
Why?
| | Medicare | 2 | 2015 | 903 | 0.140 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 55 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2010 | 673 | 0.140 |
Why?
| | Synovial Fluid | 4 | 2019 | 67 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2016 | 6447 | 0.140 |
Why?
| | Collagen | 2 | 2015 | 457 | 0.140 |
Why?
| | Patient-Centered Care | 2 | 2014 | 547 | 0.140 |
Why?
| | Complement C3 | 1 | 2019 | 187 | 0.140 |
Why?
| | Interleukin-11 | 1 | 2018 | 10 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2019 | 135 | 0.140 |
Why?
| | Fragile X Syndrome | 1 | 2019 | 119 | 0.130 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1480 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 3 | 2022 | 981 | 0.130 |
Why?
| | CD3 Complex | 3 | 2024 | 112 | 0.130 |
Why?
| | Galectins | 1 | 2018 | 26 | 0.130 |
Why?
| | Brain Diseases | 1 | 2019 | 155 | 0.130 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 231 | 0.130 |
Why?
| | RNA, Messenger | 7 | 2021 | 2803 | 0.130 |
Why?
| | Biomarkers | 4 | 2026 | 4295 | 0.130 |
Why?
| | Child, Preschool | 5 | 2016 | 11853 | 0.130 |
Why?
| | Joint Capsule | 1 | 2017 | 10 | 0.130 |
Why?
| | Hemolysis | 1 | 2019 | 242 | 0.130 |
Why?
| | MicroRNAs | 1 | 2024 | 686 | 0.130 |
Why?
| | Rho Factor | 1 | 2017 | 4 | 0.130 |
Why?
| | Infant | 4 | 2016 | 10077 | 0.130 |
Why?
| | CD28 Antigens | 3 | 2026 | 59 | 0.130 |
Why?
| | Chemotactic Factors | 1 | 2017 | 43 | 0.130 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 33 | 0.130 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2018 | 134 | 0.130 |
Why?
| | Joints | 1 | 2018 | 106 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 1999 | 372 | 0.120 |
Why?
| | Antigens, Surface | 2 | 2013 | 155 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2017 | 62 | 0.120 |
Why?
| | North Carolina | 1 | 2016 | 129 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11772 | 0.120 |
Why?
| | Interleukin-2 | 3 | 2007 | 440 | 0.120 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.120 |
Why?
| | Arthritis, Juvenile | 1 | 2017 | 60 | 0.120 |
Why?
| | Cartilage, Articular | 1 | 2020 | 349 | 0.120 |
Why?
| | Th1 Cells | 3 | 2020 | 139 | 0.120 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2017 | 130 | 0.120 |
Why?
| | Protein Kinase C | 2 | 1994 | 251 | 0.120 |
Why?
| | Gene Expression Profiling | 4 | 2026 | 1767 | 0.120 |
Why?
| | Aptamers, Nucleotide | 1 | 2017 | 87 | 0.120 |
Why?
| | Surveys and Questionnaires | 6 | 2024 | 6066 | 0.120 |
Why?
| | Spleen | 2 | 2009 | 508 | 0.120 |
Why?
| | Immunophenotyping | 2 | 2011 | 319 | 0.120 |
Why?
| | Adolescent | 8 | 2020 | 22530 | 0.120 |
Why?
| | Memory | 1 | 2018 | 295 | 0.120 |
Why?
| | Mice, Knockout | 6 | 2020 | 3124 | 0.120 |
Why?
| | Child | 6 | 2016 | 22707 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 351 | 0.110 |
Why?
| | Toll-Like Receptors | 1 | 2016 | 193 | 0.110 |
Why?
| | Interleukin-6 | 4 | 2017 | 776 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 820 | 0.110 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2015 | 35 | 0.110 |
Why?
| | Emergency Treatment | 1 | 2016 | 123 | 0.110 |
Why?
| | Laminin | 1 | 2015 | 72 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2020 | 892 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2026 | 892 | 0.110 |
Why?
| | Hand Joints | 1 | 2015 | 4 | 0.110 |
Why?
| | Histone Deacetylases | 1 | 2016 | 207 | 0.110 |
Why?
| | Disease Progression | 2 | 2013 | 2864 | 0.110 |
Why?
| | Oxidative Stress | 3 | 2020 | 1356 | 0.110 |
Why?
| | Transcriptional Activation | 1 | 2017 | 372 | 0.110 |
Why?
| | Proteoglycans | 1 | 2015 | 112 | 0.110 |
Why?
| | rho-Associated Kinases | 1 | 2015 | 82 | 0.110 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2015 | 50 | 0.110 |
Why?
| | Complement System Proteins | 1 | 2018 | 314 | 0.110 |
Why?
| | Cell Line | 5 | 2017 | 2823 | 0.110 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2597 | 0.110 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 499 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2026 | 2953 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 765 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2016 | 337 | 0.100 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 149 | 0.100 |
Why?
| | Wrist Joint | 1 | 2015 | 71 | 0.100 |
Why?
| | Cell Proliferation | 6 | 2019 | 2507 | 0.100 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1368 | 0.100 |
Why?
| | Drug Combinations | 1 | 2015 | 396 | 0.100 |
Why?
| | Cell Lineage | 2 | 2010 | 377 | 0.100 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 4 | 0.100 |
Why?
| | Thioctic Acid | 1 | 2014 | 12 | 0.100 |
Why?
| | Ultrasonography | 1 | 2018 | 785 | 0.100 |
Why?
| | Dermis | 1 | 2014 | 31 | 0.100 |
Why?
| | Phosphorylation | 2 | 2015 | 1707 | 0.100 |
Why?
| | Chemokine CXCL9 | 1 | 2013 | 38 | 0.100 |
Why?
| | Voriconazole | 1 | 2013 | 21 | 0.100 |
Why?
| | Upper Extremity | 1 | 2015 | 113 | 0.100 |
Why?
| | Cohort Studies | 6 | 2017 | 6013 | 0.100 |
Why?
| | Quality of Life | 3 | 2018 | 3204 | 0.100 |
Why?
| | CD2 Antigens | 2 | 2026 | 7 | 0.100 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2013 | 47 | 0.100 |
Why?
| | Rats | 4 | 2026 | 5584 | 0.100 |
Why?
| | Interleukin-5 | 1 | 2013 | 39 | 0.100 |
Why?
| | Range of Motion, Articular | 3 | 2013 | 429 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 484 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2007 | 385 | 0.100 |
Why?
| | Carrier Proteins | 1 | 1997 | 728 | 0.100 |
Why?
| | Calreticulin | 1 | 2013 | 22 | 0.100 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 563 | 0.100 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 144 | 0.100 |
Why?
| | Patient Care Planning | 1 | 2014 | 170 | 0.100 |
Why?
| | Antibodies, Blocking | 2 | 2007 | 37 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2930 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2026 | 2062 | 0.090 |
Why?
| | Blotting, Western | 4 | 2016 | 1179 | 0.090 |
Why?
| | Congresses as Topic | 1 | 2014 | 223 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 208 | 0.090 |
Why?
| | Myofibroblasts | 1 | 2014 | 148 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 239 | 0.090 |
Why?
| | Patient Participation | 2 | 2014 | 439 | 0.090 |
Why?
| | Osteoclasts | 3 | 2019 | 54 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2019 | 17291 | 0.090 |
Why?
| | Cell Death | 2 | 2024 | 382 | 0.090 |
Why?
| | Hip Joint | 1 | 2013 | 173 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 212 | 0.090 |
Why?
| | Infant, Premature | 1 | 2016 | 619 | 0.090 |
Why?
| | CD4 Antigens | 2 | 2007 | 137 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 14219 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 391 | 0.090 |
Why?
| | Hand Strength | 2 | 2011 | 144 | 0.090 |
Why?
| | STAT6 Transcription Factor | 1 | 2011 | 24 | 0.090 |
Why?
| | Length of Stay | 2 | 2015 | 1349 | 0.090 |
Why?
| | GATA3 Transcription Factor | 1 | 2011 | 22 | 0.090 |
Why?
| | Lung | 1 | 2025 | 4106 | 0.090 |
Why?
| | Factor Analysis, Statistical | 1 | 2012 | 291 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 838 | 0.090 |
Why?
| | United States | 7 | 2024 | 16098 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2014 | 318 | 0.080 |
Why?
| | Medicine in the Arts | 1 | 2011 | 2 | 0.080 |
Why?
| | Outpatients | 1 | 2015 | 447 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 425 | 0.080 |
Why?
| | Early Diagnosis | 1 | 2012 | 251 | 0.080 |
Why?
| | Biological Products | 1 | 2014 | 257 | 0.080 |
Why?
| | Lower Extremity | 1 | 2015 | 445 | 0.080 |
Why?
| | Major Histocompatibility Complex | 2 | 2005 | 233 | 0.080 |
Why?
| | Medicaid | 1 | 2015 | 467 | 0.080 |
Why?
| | Bleomycin | 2 | 2024 | 255 | 0.080 |
Why?
| | National Health Programs | 1 | 2010 | 23 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1371 | 0.080 |
Why?
| | Protein Binding | 2 | 2018 | 2238 | 0.080 |
Why?
| | Hospitalists | 1 | 2014 | 267 | 0.080 |
Why?
| | Cell Separation | 1 | 2011 | 305 | 0.080 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 206 | 0.080 |
Why?
| | HEK293 Cells | 2 | 2026 | 741 | 0.080 |
Why?
| | Interphase | 2 | 2001 | 38 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2013 | 1162 | 0.070 |
Why?
| | Pinch Strength | 1 | 2009 | 3 | 0.070 |
Why?
| | Binding Sites | 3 | 2019 | 1310 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1508 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2014 | 709 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2009 | 132 | 0.070 |
Why?
| | Allosteric Regulation | 2 | 2019 | 99 | 0.070 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1261 | 0.070 |
Why?
| | Receptors, Pattern Recognition | 1 | 2008 | 11 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 2 | 2019 | 90 | 0.070 |
Why?
| | Aged, 80 and over | 5 | 2015 | 8333 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 569 | 0.070 |
Why?
| | Lipopolysaccharides | 2 | 2023 | 858 | 0.070 |
Why?
| | B7 Antigens | 1 | 2008 | 18 | 0.070 |
Why?
| | Molecular Structure | 2 | 2019 | 486 | 0.070 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Prognosis | 2 | 2017 | 4316 | 0.070 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2008 | 71 | 0.060 |
Why?
| | Mycoses | 1 | 2008 | 88 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2007 | 132 | 0.060 |
Why?
| | Gene Expression | 3 | 2019 | 1476 | 0.060 |
Why?
| | Superantigens | 2 | 1997 | 70 | 0.060 |
Why?
| | Enterotoxins | 2 | 1997 | 89 | 0.060 |
Why?
| | Hybridomas | 1 | 2007 | 233 | 0.060 |
Why?
| | Connective Tissue Growth Factor | 2 | 2019 | 27 | 0.060 |
Why?
| | History, 21st Century | 1 | 2008 | 222 | 0.060 |
Why?
| | Models, Animal | 2 | 2019 | 393 | 0.060 |
Why?
| | Calcium | 3 | 2022 | 1190 | 0.060 |
Why?
| | History, 20th Century | 1 | 2008 | 328 | 0.060 |
Why?
| | Hand | 2 | 2010 | 157 | 0.060 |
Why?
| | Colorado | 1 | 2016 | 4554 | 0.060 |
Why?
| | Molecular Dynamics Simulation | 2 | 2019 | 265 | 0.060 |
Why?
| | Cytokine TWEAK | 1 | 2026 | 2 | 0.060 |
Why?
| | Fusion Regulatory Protein-1 | 2 | 1997 | 3 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2026 | 79 | 0.060 |
Why?
| | Leukocyte Elastase | 1 | 2026 | 75 | 0.060 |
Why?
| | Cell Adhesion | 1 | 2007 | 451 | 0.060 |
Why?
| | Salivary Glands | 1 | 2025 | 36 | 0.060 |
Why?
| | Genotype | 1 | 2011 | 1852 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 216 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 977 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5423 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2005 | 138 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 364 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2026 | 300 | 0.060 |
Why?
| | Pilot Projects | 1 | 2011 | 1891 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2005 | 39 | 0.050 |
Why?
| | Matrix Metalloproteinase 14 | 1 | 2024 | 3 | 0.050 |
Why?
| | Down-Regulation | 2 | 2017 | 618 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1797 | 0.050 |
Why?
| | beta 2-Glycoprotein I | 1 | 2024 | 5 | 0.050 |
Why?
| | Graft Rejection | 1 | 2008 | 521 | 0.050 |
Why?
| | Interleukin-8 | 2 | 2018 | 269 | 0.050 |
Why?
| | X-Ray Microtomography | 2 | 2015 | 108 | 0.050 |
Why?
| | Laboratory Proficiency Testing | 1 | 2024 | 9 | 0.050 |
Why?
| | NFATC Transcription Factors | 2 | 2015 | 94 | 0.050 |
Why?
| | Pathologists | 1 | 2024 | 19 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2026 | 273 | 0.050 |
Why?
| | Administration, Oral | 2 | 2017 | 866 | 0.050 |
Why?
| | Inflammation Mediators | 2 | 2017 | 506 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2026 | 276 | 0.050 |
Why?
| | Immunoassay | 1 | 2024 | 109 | 0.050 |
Why?
| | Parents | 1 | 2012 | 1403 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 847 | 0.050 |
Why?
| | Plasma Cells | 1 | 2023 | 79 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 4075 | 0.050 |
Why?
| | Collagen Type I | 2 | 2014 | 143 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2017 | 855 | 0.050 |
Why?
| | Enzyme Activation | 2 | 2014 | 762 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 265 | 0.050 |
Why?
| | Pantothenic Acid | 1 | 2022 | 5 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 177 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2024 | 192 | 0.050 |
Why?
| | Reference Values | 1 | 2024 | 798 | 0.050 |
Why?
| | Receptor, Bradykinin B1 | 1 | 2022 | 2 | 0.050 |
Why?
| | Models, Molecular | 2 | 2020 | 1598 | 0.050 |
Why?
| | Protein Kinase C-delta | 1 | 2022 | 45 | 0.050 |
Why?
| | Bradykinin | 1 | 2022 | 49 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2022 | 79 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 3155 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 717 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2022 | 153 | 0.040 |
Why?
| | Health Personnel | 1 | 2009 | 754 | 0.040 |
Why?
| | Tight Junctions | 1 | 2022 | 82 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 162 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2005 | 503 | 0.040 |
Why?
| | Benzodioxoles | 1 | 2023 | 161 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 121 | 0.040 |
Why?
| | Carbohydrate Sequence | 1 | 2001 | 29 | 0.040 |
Why?
| | Glucosylceramides | 1 | 2001 | 7 | 0.040 |
Why?
| | E-Selectin | 1 | 2001 | 61 | 0.040 |
Why?
| | Jurkat Cells | 1 | 2001 | 115 | 0.040 |
Why?
| | Propanolamines | 1 | 2001 | 40 | 0.040 |
Why?
| | Keratinocytes | 1 | 2022 | 249 | 0.040 |
Why?
| | Piperidines | 1 | 2022 | 222 | 0.040 |
Why?
| | Ergosterol | 1 | 2020 | 1 | 0.040 |
Why?
| | Virulence Factors | 1 | 2022 | 174 | 0.040 |
Why?
| | Gene Transfer, Horizontal | 1 | 2020 | 34 | 0.040 |
Why?
| | Dinoprostone | 1 | 2001 | 180 | 0.040 |
Why?
| | Pyrrolidines | 1 | 2001 | 125 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2023 | 934 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2022 | 637 | 0.040 |
Why?
| | Biopsy | 1 | 2023 | 1082 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2020 | 41 | 0.040 |
Why?
| | Coccidioides | 1 | 2019 | 6 | 0.040 |
Why?
| | Georgia | 1 | 2019 | 79 | 0.040 |
Why?
| | Visual Analog Scale | 1 | 2019 | 34 | 0.040 |
Why?
| | Mice, Inbred A | 1 | 2019 | 48 | 0.040 |
Why?
| | Interleukin-12 | 1 | 2020 | 115 | 0.040 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 2020 | 78 | 0.040 |
Why?
| | Placebos | 1 | 2020 | 193 | 0.040 |
Why?
| | Fungal Proteins | 1 | 2020 | 143 | 0.040 |
Why?
| | Aspergillosis | 1 | 2019 | 24 | 0.040 |
Why?
| | Symbiosis | 1 | 2020 | 72 | 0.040 |
Why?
| | U937 Cells | 1 | 2019 | 28 | 0.040 |
Why?
| | Receptors, Interleukin-7 | 1 | 2019 | 28 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2001 | 243 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 61 | 0.040 |
Why?
| | Epigenetic Repression | 1 | 2019 | 4 | 0.040 |
Why?
| | Cryptococcosis | 1 | 2019 | 31 | 0.040 |
Why?
| | Ankle Joint | 1 | 2020 | 122 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2011 | 5905 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2019 | 113 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2019 | 85 | 0.040 |
Why?
| | Patient Discharge | 2 | 2016 | 992 | 0.040 |
Why?
| | fas Receptor | 1 | 1999 | 91 | 0.040 |
Why?
| | Infliximab | 1 | 2019 | 111 | 0.040 |
Why?
| | Administration, Topical | 1 | 1999 | 153 | 0.040 |
Why?
| | Peptides | 1 | 2005 | 998 | 0.040 |
Why?
| | Vital Capacity | 1 | 2019 | 292 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2019 | 56 | 0.040 |
Why?
| | Gene Deletion | 1 | 2020 | 391 | 0.040 |
Why?
| | Drug Discovery | 1 | 2019 | 153 | 0.030 |
Why?
| | Methylation | 1 | 2019 | 242 | 0.030 |
Why?
| | Maze Learning | 1 | 2018 | 105 | 0.030 |
Why?
| | Receptors, Notch | 1 | 2019 | 90 | 0.030 |
Why?
| | Interleukin-11 Receptor alpha Subunit | 1 | 2018 | 4 | 0.030 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 41 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2019 | 147 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 630 | 0.030 |
Why?
| | Thymus Gland | 1 | 1999 | 312 | 0.030 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2018 | 30 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2019 | 321 | 0.030 |
Why?
| | Hemoglobins | 1 | 2020 | 386 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 1997 | 40 | 0.030 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 38 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2018 | 268 | 0.030 |
Why?
| | Nerve Fibers | 1 | 2018 | 105 | 0.030 |
Why?
| | Receptors, Interleukin-2 | 1 | 1997 | 64 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2018 | 200 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 75 | 0.030 |
Why?
| | Binding, Competitive | 1 | 1997 | 185 | 0.030 |
Why?
| | Serum Response Element | 1 | 2017 | 6 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Hyperalgesia | 1 | 2018 | 127 | 0.030 |
Why?
| | Zymosan | 1 | 2017 | 39 | 0.030 |
Why?
| | Follistatin-Related Proteins | 1 | 2016 | 2 | 0.030 |
Why?
| | Nectins | 1 | 2016 | 7 | 0.030 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2016 | 6 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2022 | 740 | 0.030 |
Why?
| | Paclitaxel | 1 | 2018 | 257 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1407 | 0.030 |
Why?
| | Dexamethasone | 1 | 1999 | 365 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2001 | 2883 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2016 | 94 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 172 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1997 | 174 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2020 | 492 | 0.030 |
Why?
| | Neuralgia | 1 | 2018 | 140 | 0.030 |
Why?
| | Phylogeny | 1 | 2020 | 917 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 219 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 475 | 0.030 |
Why?
| | Clone Cells | 1 | 1996 | 263 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2011 | 1323 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1997 | 220 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 456 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1435 | 0.030 |
Why?
| | Knee Joint | 1 | 2019 | 428 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 333 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2019 | 519 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 365 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 497 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 389 | 0.030 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2014 | 18 | 0.030 |
Why?
| | Arthrodesis | 1 | 2015 | 35 | 0.030 |
Why?
| | Cell Division | 1 | 1996 | 756 | 0.030 |
Why?
| | RANK Ligand | 1 | 2014 | 27 | 0.030 |
Why?
| | Cycloheximide | 1 | 1994 | 42 | 0.030 |
Why?
| | Databases, Protein | 1 | 2014 | 88 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 1193 | 0.030 |
Why?
| | Cell Cycle | 1 | 1997 | 598 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 441 | 0.030 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2014 | 4 | 0.030 |
Why?
| | Spinal Cord | 1 | 2017 | 382 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 16 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2014 | 14 | 0.030 |
Why?
| | Sulfurtransferases | 1 | 2014 | 10 | 0.030 |
Why?
| | Lymphoid Tissue | 1 | 2014 | 78 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 22 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2019 | 602 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 146 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1734 | 0.030 |
Why?
| | Mycobacterium | 1 | 2014 | 101 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2014 | 85 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 546 | 0.020 |
Why?
| | Databases, Factual | 1 | 2019 | 1490 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 302 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2014 | 80 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2014 | 95 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 451 | 0.020 |
Why?
| | Immunoblotting | 1 | 2013 | 295 | 0.020 |
Why?
| | Biomimetic Materials | 1 | 2013 | 78 | 0.020 |
Why?
| | Cartilage | 1 | 2014 | 197 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 412 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 87 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1048 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2524 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2013 | 110 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 376 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2018 | 835 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1716 | 0.020 |
Why?
| | Reoperation | 1 | 2015 | 633 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 408 | 0.020 |
Why?
| | Arginine | 1 | 2013 | 264 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 180 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 372 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1547 | 0.020 |
Why?
| | Medicine in Literature | 1 | 2011 | 4 | 0.020 |
Why?
| | History, 17th Century | 1 | 2011 | 14 | 0.020 |
Why?
| | History, 16th Century | 1 | 2011 | 15 | 0.020 |
Why?
| | Paleopathology | 1 | 2011 | 11 | 0.020 |
Why?
| | Linear Models | 1 | 2013 | 845 | 0.020 |
Why?
| | History, Ancient | 1 | 2011 | 53 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 150 | 0.020 |
Why?
| | England | 1 | 2010 | 108 | 0.020 |
Why?
| | Computational Biology | 1 | 2014 | 669 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 825 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2014 | 777 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2011 | 310 | 0.020 |
Why?
| | Models, Statistical | 1 | 2013 | 671 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2014 | 967 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2923 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1808 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7202 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7123 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1061 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2017 | 2382 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2381 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2003 | 536 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 10885 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|